Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis
Background and Aims Accurate diagnosis of non‐alcoholic steatohepatitis (NASH) from non‐alcoholic fatty liver disease (NAFLD) is clinically important. Therefore, there is a need for easier ways of diagnosing NASH. In this study, we investigated the serum fatty acid composition and evaluated the poss...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2019-10, Vol.34 (10), p.1829-1835 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1835 |
|---|---|
| container_issue | 10 |
| container_start_page | 1829 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 34 |
| creator | Yamada, Kazutoshi Mizukoshi, Eishiro Seike, Takuya Horii, Rika Terashima, Takeshi Iida, Noriho Kitahara, Masaaki Sunagozaka, Hajime Arai, Kuniaki Yamashita, Tatsuya Honda, Masao Takamura, Toshinari Harada, Kenichi Kaneko, Shuichi |
| description | Background and Aims
Accurate diagnosis of non‐alcoholic steatohepatitis (NASH) from non‐alcoholic fatty liver disease (NAFLD) is clinically important. Therefore, there is a need for easier ways of diagnosing NASH. In this study, we investigated the serum fatty acid composition and evaluated the possibility of using the serum fatty acid composition as a diagnostic marker of NASH.
Methods
The subjects were 78 NAFLD patients (non‐alcoholic fatty liver [NAFL]: 30, NASH: 48) and 24 healthy individuals. Fatty acids extracted from the liver tissue and serum were identified and quantified by gas chromatography. In addition, we evaluated the relationship between serum and liver tissue fatty acid composition, patient background, and liver histology. The diagnostic performance of NASH was evaluated by calculating the area under the receiver operating characteristic (AUROC).
Results
The results of the fatty acid analysis showed the C16:1n7/C16:0 ratio to have the strongest correlation between serum and liver tissue (r = 0.865, P |
| doi_str_mv | 10.1111/jgh.14654 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2191010529</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2191010529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4194-96b216cb5de44f232d36977f1d2a9f0d246b56c6a5a17980769d2ad3224f36723</originalsourceid><addsrcrecordid>eNp1kL1OwzAUhS0EouVn4AVQJBYY0vrajhOzoQpaUCUGymw5idOmpHGxE6FuPALPyJPgksKAxF3OcL97dO5B6AzwAPwMl_PFABiP2B7qA2M4hJjxfdTHCUShoCB66Mi5JcaY4Tg6RD2KE84IFX00e9K2XQUj4NdQx8Ot4sCqpjSBcoEK8lLNa-OaMgtWyr5oGxTGBrWpP98_VJWZhan8yjVaNWah1_6wKd0JOihU5fTpTo_R893tbDQJp4_j-9HNNMwYCBYKnhLgWRrlmrGCUJJTLuK4gJwoUeCcMJ5GPOMqUhCLBMdc-E1OCWEF5TGhx-iy811b89pq18hV6TJdVarWpnWSgAAMOCLCoxd_0KVpbe3TSUKB0cQHSjx11VGZNc5ZXci1Lf3fGwlYbquWvmr5XbVnz3eObbrS-S_5060Hhh3wVlZ687-TfBhPOssv0RaFdA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2314381948</pqid></control><display><type>article</type><title>Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Yamada, Kazutoshi ; Mizukoshi, Eishiro ; Seike, Takuya ; Horii, Rika ; Terashima, Takeshi ; Iida, Noriho ; Kitahara, Masaaki ; Sunagozaka, Hajime ; Arai, Kuniaki ; Yamashita, Tatsuya ; Honda, Masao ; Takamura, Toshinari ; Harada, Kenichi ; Kaneko, Shuichi</creator><creatorcontrib>Yamada, Kazutoshi ; Mizukoshi, Eishiro ; Seike, Takuya ; Horii, Rika ; Terashima, Takeshi ; Iida, Noriho ; Kitahara, Masaaki ; Sunagozaka, Hajime ; Arai, Kuniaki ; Yamashita, Tatsuya ; Honda, Masao ; Takamura, Toshinari ; Harada, Kenichi ; Kaneko, Shuichi</creatorcontrib><description>Background and Aims
Accurate diagnosis of non‐alcoholic steatohepatitis (NASH) from non‐alcoholic fatty liver disease (NAFLD) is clinically important. Therefore, there is a need for easier ways of diagnosing NASH. In this study, we investigated the serum fatty acid composition and evaluated the possibility of using the serum fatty acid composition as a diagnostic marker of NASH.
Methods
The subjects were 78 NAFLD patients (non‐alcoholic fatty liver [NAFL]: 30, NASH: 48) and 24 healthy individuals. Fatty acids extracted from the liver tissue and serum were identified and quantified by gas chromatography. In addition, we evaluated the relationship between serum and liver tissue fatty acid composition, patient background, and liver histology. The diagnostic performance of NASH was evaluated by calculating the area under the receiver operating characteristic (AUROC).
Results
The results of the fatty acid analysis showed the C16:1n7/C16:0 ratio to have the strongest correlation between serum and liver tissue (r = 0.865, P < 0.0001). The serum C16:1n7/C16:0 ratio in the NASH group was higher compared with that in the NAFL group (P = 0.0007). Evaluation of the association of the serum C16:1n7/C16:0 ratio with liver histology revealed significant correlation with lobular inflammation score, ballooning score, and fibrosis score. The AUROC for predicting NASH in all NAFLD patients was 0.7097. The AUROC was nearly equivalent even when the study subjects were restricted to patients with a fibrosis score ≤ 2 only (AUROC 0.6917).
Conclusion
Measuring the serum C16:1n7/C16:0 ratio may be an effective non‐invasive method for diagnosing NASH, particularly in its early stages.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.14654</identifier><identifier>PMID: 30864239</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Balloon treatment ; Biomarkers - blood ; Case-Control Studies ; Early Diagnosis ; fatty acid ; Fatty acid composition ; Fatty acids ; Fatty Acids - blood ; Fatty liver ; Female ; Fibrosis ; Gas chromatography ; Histology ; Humans ; Liver ; Liver - metabolism ; Liver - pathology ; Liver diseases ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease - blood ; Non-alcoholic Fatty Liver Disease - diagnosis ; Non-alcoholic Fatty Liver Disease - pathology ; non‐alcoholic fatty liver disease ; palmitic acid ; palmitoleic acid ; Predictive Value of Tests ; Prognosis ; Reproducibility of Results</subject><ispartof>Journal of gastroenterology and hepatology, 2019-10, Vol.34 (10), p.1829-1835</ispartof><rights>2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd</rights><rights>2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4194-96b216cb5de44f232d36977f1d2a9f0d246b56c6a5a17980769d2ad3224f36723</citedby><cites>FETCH-LOGICAL-c4194-96b216cb5de44f232d36977f1d2a9f0d246b56c6a5a17980769d2ad3224f36723</cites><orcidid>0000-0002-4611-448X ; 0000-0003-3053-4356 ; 0000-0002-4787-6910</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.14654$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.14654$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30864239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamada, Kazutoshi</creatorcontrib><creatorcontrib>Mizukoshi, Eishiro</creatorcontrib><creatorcontrib>Seike, Takuya</creatorcontrib><creatorcontrib>Horii, Rika</creatorcontrib><creatorcontrib>Terashima, Takeshi</creatorcontrib><creatorcontrib>Iida, Noriho</creatorcontrib><creatorcontrib>Kitahara, Masaaki</creatorcontrib><creatorcontrib>Sunagozaka, Hajime</creatorcontrib><creatorcontrib>Arai, Kuniaki</creatorcontrib><creatorcontrib>Yamashita, Tatsuya</creatorcontrib><creatorcontrib>Honda, Masao</creatorcontrib><creatorcontrib>Takamura, Toshinari</creatorcontrib><creatorcontrib>Harada, Kenichi</creatorcontrib><creatorcontrib>Kaneko, Shuichi</creatorcontrib><title>Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background and Aims
Accurate diagnosis of non‐alcoholic steatohepatitis (NASH) from non‐alcoholic fatty liver disease (NAFLD) is clinically important. Therefore, there is a need for easier ways of diagnosing NASH. In this study, we investigated the serum fatty acid composition and evaluated the possibility of using the serum fatty acid composition as a diagnostic marker of NASH.
Methods
The subjects were 78 NAFLD patients (non‐alcoholic fatty liver [NAFL]: 30, NASH: 48) and 24 healthy individuals. Fatty acids extracted from the liver tissue and serum were identified and quantified by gas chromatography. In addition, we evaluated the relationship between serum and liver tissue fatty acid composition, patient background, and liver histology. The diagnostic performance of NASH was evaluated by calculating the area under the receiver operating characteristic (AUROC).
Results
The results of the fatty acid analysis showed the C16:1n7/C16:0 ratio to have the strongest correlation between serum and liver tissue (r = 0.865, P < 0.0001). The serum C16:1n7/C16:0 ratio in the NASH group was higher compared with that in the NAFL group (P = 0.0007). Evaluation of the association of the serum C16:1n7/C16:0 ratio with liver histology revealed significant correlation with lobular inflammation score, ballooning score, and fibrosis score. The AUROC for predicting NASH in all NAFLD patients was 0.7097. The AUROC was nearly equivalent even when the study subjects were restricted to patients with a fibrosis score ≤ 2 only (AUROC 0.6917).
Conclusion
Measuring the serum C16:1n7/C16:0 ratio may be an effective non‐invasive method for diagnosing NASH, particularly in its early stages.</description><subject>Adult</subject><subject>Aged</subject><subject>Balloon treatment</subject><subject>Biomarkers - blood</subject><subject>Case-Control Studies</subject><subject>Early Diagnosis</subject><subject>fatty acid</subject><subject>Fatty acid composition</subject><subject>Fatty acids</subject><subject>Fatty Acids - blood</subject><subject>Fatty liver</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Gas chromatography</subject><subject>Histology</subject><subject>Humans</subject><subject>Liver</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Non-alcoholic Fatty Liver Disease - blood</subject><subject>Non-alcoholic Fatty Liver Disease - diagnosis</subject><subject>Non-alcoholic Fatty Liver Disease - pathology</subject><subject>non‐alcoholic fatty liver disease</subject><subject>palmitic acid</subject><subject>palmitoleic acid</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Reproducibility of Results</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kL1OwzAUhS0EouVn4AVQJBYY0vrajhOzoQpaUCUGymw5idOmpHGxE6FuPALPyJPgksKAxF3OcL97dO5B6AzwAPwMl_PFABiP2B7qA2M4hJjxfdTHCUShoCB66Mi5JcaY4Tg6RD2KE84IFX00e9K2XQUj4NdQx8Ot4sCqpjSBcoEK8lLNa-OaMgtWyr5oGxTGBrWpP98_VJWZhan8yjVaNWah1_6wKd0JOihU5fTpTo_R893tbDQJp4_j-9HNNMwYCBYKnhLgWRrlmrGCUJJTLuK4gJwoUeCcMJ5GPOMqUhCLBMdc-E1OCWEF5TGhx-iy811b89pq18hV6TJdVarWpnWSgAAMOCLCoxd_0KVpbe3TSUKB0cQHSjx11VGZNc5ZXci1Lf3fGwlYbquWvmr5XbVnz3eObbrS-S_5060Hhh3wVlZ687-TfBhPOssv0RaFdA</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Yamada, Kazutoshi</creator><creator>Mizukoshi, Eishiro</creator><creator>Seike, Takuya</creator><creator>Horii, Rika</creator><creator>Terashima, Takeshi</creator><creator>Iida, Noriho</creator><creator>Kitahara, Masaaki</creator><creator>Sunagozaka, Hajime</creator><creator>Arai, Kuniaki</creator><creator>Yamashita, Tatsuya</creator><creator>Honda, Masao</creator><creator>Takamura, Toshinari</creator><creator>Harada, Kenichi</creator><creator>Kaneko, Shuichi</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4611-448X</orcidid><orcidid>https://orcid.org/0000-0003-3053-4356</orcidid><orcidid>https://orcid.org/0000-0002-4787-6910</orcidid></search><sort><creationdate>201910</creationdate><title>Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis</title><author>Yamada, Kazutoshi ; Mizukoshi, Eishiro ; Seike, Takuya ; Horii, Rika ; Terashima, Takeshi ; Iida, Noriho ; Kitahara, Masaaki ; Sunagozaka, Hajime ; Arai, Kuniaki ; Yamashita, Tatsuya ; Honda, Masao ; Takamura, Toshinari ; Harada, Kenichi ; Kaneko, Shuichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4194-96b216cb5de44f232d36977f1d2a9f0d246b56c6a5a17980769d2ad3224f36723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Balloon treatment</topic><topic>Biomarkers - blood</topic><topic>Case-Control Studies</topic><topic>Early Diagnosis</topic><topic>fatty acid</topic><topic>Fatty acid composition</topic><topic>Fatty acids</topic><topic>Fatty Acids - blood</topic><topic>Fatty liver</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Gas chromatography</topic><topic>Histology</topic><topic>Humans</topic><topic>Liver</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Non-alcoholic Fatty Liver Disease - blood</topic><topic>Non-alcoholic Fatty Liver Disease - diagnosis</topic><topic>Non-alcoholic Fatty Liver Disease - pathology</topic><topic>non‐alcoholic fatty liver disease</topic><topic>palmitic acid</topic><topic>palmitoleic acid</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Reproducibility of Results</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamada, Kazutoshi</creatorcontrib><creatorcontrib>Mizukoshi, Eishiro</creatorcontrib><creatorcontrib>Seike, Takuya</creatorcontrib><creatorcontrib>Horii, Rika</creatorcontrib><creatorcontrib>Terashima, Takeshi</creatorcontrib><creatorcontrib>Iida, Noriho</creatorcontrib><creatorcontrib>Kitahara, Masaaki</creatorcontrib><creatorcontrib>Sunagozaka, Hajime</creatorcontrib><creatorcontrib>Arai, Kuniaki</creatorcontrib><creatorcontrib>Yamashita, Tatsuya</creatorcontrib><creatorcontrib>Honda, Masao</creatorcontrib><creatorcontrib>Takamura, Toshinari</creatorcontrib><creatorcontrib>Harada, Kenichi</creatorcontrib><creatorcontrib>Kaneko, Shuichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamada, Kazutoshi</au><au>Mizukoshi, Eishiro</au><au>Seike, Takuya</au><au>Horii, Rika</au><au>Terashima, Takeshi</au><au>Iida, Noriho</au><au>Kitahara, Masaaki</au><au>Sunagozaka, Hajime</au><au>Arai, Kuniaki</au><au>Yamashita, Tatsuya</au><au>Honda, Masao</au><au>Takamura, Toshinari</au><au>Harada, Kenichi</au><au>Kaneko, Shuichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2019-10</date><risdate>2019</risdate><volume>34</volume><issue>10</issue><spage>1829</spage><epage>1835</epage><pages>1829-1835</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aims
Accurate diagnosis of non‐alcoholic steatohepatitis (NASH) from non‐alcoholic fatty liver disease (NAFLD) is clinically important. Therefore, there is a need for easier ways of diagnosing NASH. In this study, we investigated the serum fatty acid composition and evaluated the possibility of using the serum fatty acid composition as a diagnostic marker of NASH.
Methods
The subjects were 78 NAFLD patients (non‐alcoholic fatty liver [NAFL]: 30, NASH: 48) and 24 healthy individuals. Fatty acids extracted from the liver tissue and serum were identified and quantified by gas chromatography. In addition, we evaluated the relationship between serum and liver tissue fatty acid composition, patient background, and liver histology. The diagnostic performance of NASH was evaluated by calculating the area under the receiver operating characteristic (AUROC).
Results
The results of the fatty acid analysis showed the C16:1n7/C16:0 ratio to have the strongest correlation between serum and liver tissue (r = 0.865, P < 0.0001). The serum C16:1n7/C16:0 ratio in the NASH group was higher compared with that in the NAFL group (P = 0.0007). Evaluation of the association of the serum C16:1n7/C16:0 ratio with liver histology revealed significant correlation with lobular inflammation score, ballooning score, and fibrosis score. The AUROC for predicting NASH in all NAFLD patients was 0.7097. The AUROC was nearly equivalent even when the study subjects were restricted to patients with a fibrosis score ≤ 2 only (AUROC 0.6917).
Conclusion
Measuring the serum C16:1n7/C16:0 ratio may be an effective non‐invasive method for diagnosing NASH, particularly in its early stages.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30864239</pmid><doi>10.1111/jgh.14654</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4611-448X</orcidid><orcidid>https://orcid.org/0000-0003-3053-4356</orcidid><orcidid>https://orcid.org/0000-0002-4787-6910</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2019-10, Vol.34 (10), p.1829-1835 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2191010529 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Balloon treatment Biomarkers - blood Case-Control Studies Early Diagnosis fatty acid Fatty acid composition Fatty acids Fatty Acids - blood Fatty liver Female Fibrosis Gas chromatography Histology Humans Liver Liver - metabolism Liver - pathology Liver diseases Male Middle Aged Non-alcoholic Fatty Liver Disease - blood Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - pathology non‐alcoholic fatty liver disease palmitic acid palmitoleic acid Predictive Value of Tests Prognosis Reproducibility of Results |
| title | Serum C16:1n7/C16:0 ratio as a diagnostic marker for non‐alcoholic steatohepatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A01%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20C16:1n7/C16:0%20ratio%20as%20a%20diagnostic%20marker%20for%20non%E2%80%90alcoholic%20steatohepatitis&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Yamada,%20Kazutoshi&rft.date=2019-10&rft.volume=34&rft.issue=10&rft.spage=1829&rft.epage=1835&rft.pages=1829-1835&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.14654&rft_dat=%3Cproquest_cross%3E2191010529%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2314381948&rft_id=info:pmid/30864239&rfr_iscdi=true |